Tomasz Skoczylas

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Yelena Y. Janjigian, Kohei Shitara, Markus Moehler et al. · The Lancet · 2021 · 2.9K citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

Kohei Shitara, Jaffer A. Ajani, Markus Moehler et al. · Nature · 2022 · 442 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries

Stephen R Knight, Riinu Pius, Thomas M Drake et al. · The Lancet · 2021 · 310 citations · Full text

Medicine, Oncology, Surgery +13

First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial

Yelena Y. Janjigian, Jaffer A. Ajani, Markus Moehler et al. · Journal of Clinical Oncology · 2024 · 216 citations · Full text

Medicine, Oncology, Gastrointestinal Oncology +1

LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study

Markus Moehler, Kohei Shitara, Marcelo Garrido et al. · Annals of Oncology · 2020 · 205 citations

Medicine, Oncology, Pharmacology +14